Hong Kong researchers study bispecific antibody for HIV in mice | Study links obesity, hepatitis to rising liver cancer incidence | Surgical transfusions may be linked to risk for venous thromboembolism
June 18, 2018
News for the transfusion medicine and cellular therapy community
Researchers at Hong Kong University's AIDS Institute found that a bispecific antibody was associated with viral control and elimination of infected cells, according to an animal study in the Journal of Clinical Investigation. The study team said the antibody could be ready for clinical trials in three to five years.
The obesity epidemic and an increase in hepatitis infections have fueled an increase in liver cancer in the US and three other developed countries over the past 25 years, researchers reported at the Global Hepatitis Summit. The UK has the highest incidence of liver cancer at 9.6 per 100,000 people, followed by the US at 9.2 per 100,000, Australia at 7.4 per 100,000 and Canada at 6.0 per 100,000, with similar rankings found for liver cancer mortality.
Bluebird bio reported at the European Hematology Association meeting last week that changes to its gene therapy candidate LentiGlobin boosted the experimental therapy's efficacy based on results from its early-stage study. The trial consists of four patients with sickle cell disease, who are now producing a median of 39% of healthy hemoglobin in their blood after receiving the treatment.
Acceleron Pharma's luspatercept demonstrated treatment benefit in two midstage trials evaluating the drug in patients with beta thalassemia, according to a presentation at the meeting of the European Hematology Association.
The data showed 41% of transfusion-dependent patients experienced at least a 33% reduction in red blood cell transfusion burden, while 53% of the non-transfusion-dependent group achieved at least a 1 g/dL increase in hemoglobin from baseline.
At the annual meeting of the European Hematology Association, MorphoSys presented data from its Phase II trial evaluating the efficacy and safety of its drug candidate MOR208 combined with idelalisib indicated for patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma who couldn't tolerate or whose disease progressed with ibrutinib. Preliminary efficacy analysis showed an overall response rate of 82%, with one complete and eight partial responses, and neutropenia and anemia being the most common treatment-emerging adverse events.
AABB released a detailed program guide for the 2018 AABB Annual Meeting. The schedule outlines the full education program for the meeting, to be held Oct. 13-16 in Boston. More than 140 educational offerings include sessions on genotype matching, perioperative coagulopathy, donor compliance among men who have sex with men (MSM) and extending the storage of blood products. The meeting will also provide approximately 650 scientific and administrative abstracts and an exhibit hall with about 200 companies displaying state-of-the-art products and services. Additional information about the meeting, pre-meeting workshops, registration and hotels can be found on the 2018 AABB Annual Meeting website.